The Burden of Rheumatoid Arthritis and Low Back Pain in North Africa and Middle East From 1990 to 2019: Results From the Global Burden of Disease Study 2019 Publisher Pubmed



Sanjari M¹ ; Noorali S¹ ; Behnoush AH² ; Saeedimoghaddam S^{2, 3} ; Fahimfar N¹ ; Azangoukhyavy M^{2, 4} ; Yousefi S¹ ; Ebrahimi N² ; Yarmohammadi H^{1, 5} ; Rashidi MM² ; Ostovar A¹ ; Larijani B⁶ Show Affiliations
Source: International Journal of Rheumatic Diseases Published:2023

Abstract

Background: Rheumatoid arthritis (RA) and low back pain (LBP) are among the most prevalent musculoskeletal disorders (MSDs). The need for investigation of regional and local patterns of these two MSDs seems inevitable for better policy-making. The current study presents updated results of the Global Burden of Disease (GBD) Study 2019 and reports the burden of RA and LBP in North Africa and Middle East (NAME) countries from 1990 to 2019. Methods: Incidence, prevalence, mortality, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and risk factors, including high body mass index, occupational ergonomic factors, and smoking, were extracted based on the GBD 2019 data. Results: The age-standardized prevalence and mortality of RA were 120.6 (95% uncertainty interval [95% UI] 107.0–135.7) and 0.1 (95% UI 0.1–0.2) per 100 000 population in 2019 with 28.3% (95% UI 25.5%–30.9%) increase and 7.5% (95% UI −37.5% to 32.5%) decrease since 1990, respectively. Turkey had the highest age-standardized incidence, prevalence, and DALYs of RA in 2019. All RA burden measures were higher for women; however, the incidence was almost the same at ages greater than 65 years. The age-standardized prevalence and DALYs of LBP were 7668.2 (95% UI 6798.0–8636.3) and 862 (95% UI 605.5–1153.3) in 2019, which had decreased by 5.8% (95% UI −7.4% to −4.3%) and 6.0% (95% UI −7.7% to −4.2%) since 1990, respectively. Moreover, although Turkey had the highest incidence and prevalence in 1990, Iran was at the top in 2019. The regional age-standardized DALY rates due to RA and LBP attributed to smoking were 1.7 (95% UI 0.5–3.2) and 139.4 (95% UI 87.3–198.8) in 2019, respectively, which had decreased 2.2% (95% UI −19.2% to 13.7%) and 15.4% (95% UI −19.4% to −10.5%) since 1990, respectively. Conclusion: RA still imposes a significant burden in the NAME region as the burden measures have increased from 1990 to 2019. On the other hand, regarding LBP, a decreasing pattern was observed. Differences among the countries and between ages and genders can have implications, and the results of this study may be helpful for policy-makers in the NAME countries. © 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.